2026 Partner in Progress: ImmunityBio

BCAN is proud to collaborate with ImmunityBio in our shared commitment to improving the lives of bladder cancer patients and their families—both now and in the future.

The following content is sponsored by ImmunityBio.

At ImmunityBio, we are committed to developing innovative immunotherapies designed to improve the lives of people living with serious diseases. Our research focuses on harnessing the body’s immune system to help fight disease while supporting long-term immune health.

This includes Anktiva® (nogapendekin alfa inbakicept-pmln), an immunotherapy indicated for the treatment of adults with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (CIS), with or without papillary tumors.

What is Anktiva® (nogapendekin alfa inbakicept-pmln)?

Anktiva is the first U.S. FDA-approved immunotherapy that activates a type of immune cell called a natural killer (NK) cell, whose goal is to attack and kill attack and kill non-muscle invasive bladder cancer cells.¹

Anktiva is used in combination with bacillus Calmette-Guérin (BCG), a standard treatment for non-muscle invasive bladder cancer (NMIBC), in adults whose cancer did not respond adequately to BCG alone or returned after an initial response. These people have what is termed BCG-unresponsive NMIBC CIS.

You can learn more in ImmunityBio’s Getting Started with Anktiva Guide for patients.

References:

1. Anktiva (nogapendekin alfa inbakicept-pmln) prescribing information. ImmunityBio, 2024

Important Safety Information:

INDICATION AND USAGE

ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS

Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION

For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS

The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about Anktiva, please see the Full Prescribing Information at www.anktiva.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482).

Who Should Consider Anktiva?

Anktiva is a treatment for adults who have all the following:

• High-risk non-muscle invasive bladder cancer (NMIBC)
• NMIBC that did not or is no longer responding to BCG therapy alone (BCG-unresponsive)
• NMIBC that has not grown beyond the inner lining of the bladder to the muscle underneath (called carcinoma in situ or CIS disease)
• NMIBC with or without small finger-like tumor growths that project away from the bladder wall into the bladder (papillary disease)

How is Anktiva Administered?

Anktiva and BCG are combined in one syringe and administered directly into the bladder through a tube called a catheter. The procedure is performed by a urologist (or qualified health care provider) once a week for six weeks for the induction phase, followed by the maintenance phase. This is the same process as when BCG is administered alone. The post-treatment directions are like those for after BCG treatment as well. A second treatment course may be administered if the tumor does not shrink at three months.

Patient Assistance Program

The ImmunityBio CARE™ program is designed to help patients access ImmunityBio’s innovative treatment for BCG-unresponsive NMIBC CIS. The program offers services and resources to determine if your insurance covers Anktiva®, including, benefits investigation, prior authorization support and tracking, coding and billing assistance, claim denial guidance, and payer-specific appeal assistance.

Click here to learn more about ImmunityBio.